Used in the treatment of inflammatory diseases and certain cancers by targeting the IL-1 receptor accessory protein (IL-1RAP), this antibody blocks signaling pathways involved in chronic inflammation and tumor progression. It shows promise in conditions like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) by enabling immune-mediated destruction of malignant cells. Additionally, it is being explored for autoimmune and autoinflammatory disorders where IL-1 pathway overactivation plays a key role. Its high specificity allows for targeted therapy with potentially fewer side effects compared to broad immunosuppressants.